ADA-friendly PDF: Dana-Farber Consensus Statement - T-DXd in HER2-low BC

Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.